Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
survodutide in Chinese Participants With Overweight or Obesity
NCT06214741Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2024
- Primary completion
- Jul 2025
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of survodutide in obesity, sponsored by Boehringer Ingelheim. Started Feb 2024; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06214741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06214741.